Gaurav Kharya
Overview
Explore the profile of Gaurav Kharya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nirmal G, Kharya G, Shankar R, Singh S, Paul S, Choudhary M, et al.
Pediatr Hematol Oncol
. 2024 Sep;
41(8):557-571.
PMID: 39310983
Anti-thymocyte globulin (ATG) forms an essential component of conditioning in hematopoietic stem cell transplantation (HSCT). Due to the shift of donor preference to alternate donors, reliance on rabbit-ATG (rATG) has...
2.
Olowoselu O, Okunade K, Oyedeji O, Davies N, Ajie O, Adewoyin A, et al.
Cureus
. 2024 May;
16(4):e58195.
PMID: 38741860
Background: Haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for sickle cell anaemia (SCA). While HSCT offers the possibility of disease remission, it can also lead to long-term...
3.
Giardino S, Eikema D, Piepenbroek B, Algeri M, Ayas M, Faraci M, et al.
Am J Hematol
. 2024 Mar;
99(6):1066-1076.
PMID: 38497679
Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the...
4.
Paul S, Nirmal G, Chadha V, Sharma R, Kochar I, Jerath N, et al.
J Pediatr Hematol Oncol
. 2023 Nov;
46(1):e91-e93.
PMID: 38019672
Sirolimus (mammalian target of rapamycin inhibitor) is a potent immunosuppressive agent, used in patients receiving hematopoietic stem cell transplant (HSCT) for Graft vs Host disease prophylaxis. Compared to calcineurin inhibitors,...
5.
Yadav S, Raj R, Uppuluri R, Choudhary D, Doval D, Dua V, et al.
Pediatr Hematol Oncol
. 2023 Nov;
41(2):169-171.
PMID: 38013455
No abstract available.
6.
Nishimura A, Uppuluri R, Raj R, Swaminathan V, Cheng Y, Abu-Arja R, et al.
J Clin Immunol
. 2023 Jul;
43(8):1827-1839.
PMID: 37454339
Purpose: X-linked agammaglobulinemia (XLA) is an inborn error of immunity caused by variants in Bruton's tyrosine kinase (BTK). XLA patients require lifelong immunoglobulin replacement therapy (IgRT). Only few XLA patients...
7.
Sagar S, Faizan M, Chaudhary N, Singh V, Singh P, Gheware A, et al.
Cell Death Dis
. 2023 May;
14(5):324.
PMID: 37173333
Mesenchymal stem cell (MSC) transplantation alleviates metabolic defects in diseased recipient cells by intercellular mitochondrial transport (IMT). However, the effect of host metabolic conditions on IMT and thereby on the...
8.
Ankur K, Prasad A, Kharya G, Chetry S
Neoreviews
. 2023 Mar;
24(3):e184-e187.
PMID: 36854850
No abstract available.
9.
Kharya G, Jaiswal S, Bhat S, Raj R, Yadav S, Dua V, et al.
Transplant Cell Ther
. 2022 Dec;
29(3):199.e1-199.e10.
PMID: 36572385
Allogenic hematopoietic cell transplantation (HCT) is the best curative approach for patients with severe aplastic anemia (SAA). The outcomes of HCT from haploidentical family donors (HFDs) have improved, making it...
10.
Kharya G, Sapkota S, Teotia N, Chaudhary M, Swathymon K, Chodan P, et al.
Bone Marrow Transplant
. 2022 Nov;
58(2):233-236.
PMID: 36434270
No abstract available.